Cargando…

Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials

Previous clinical trials have investigated the effect of glucocorticoid therapy in acute respiratory distress syndrome (ARDS), with controversial results, particularly with regard to the early administration of low dose glucocorticoid. The present meta-analysis aimed to assess whether the applicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhi-Gang, Lei, Xiao-Li, Li, Xiao-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377286/
https://www.ncbi.nlm.nih.gov/pubmed/28413460
http://dx.doi.org/10.3892/etm.2017.4154
_version_ 1782519284023427072
author Yang, Zhi-Gang
Lei, Xiao-Li
Li, Xiao-Liang
author_facet Yang, Zhi-Gang
Lei, Xiao-Li
Li, Xiao-Liang
author_sort Yang, Zhi-Gang
collection PubMed
description Previous clinical trials have investigated the effect of glucocorticoid therapy in acute respiratory distress syndrome (ARDS), with controversial results, particularly with regard to the early administration of low dose glucocorticoid. The present meta-analysis aimed to assess whether the application of glucocorticoid was able to reduce mortality in patients with ARDS. A literature search was performed using online databases, including MEDLINE, Embase, Cochrane and CNKI regardless of whether the studies were published in English or Chinese. Following assessment via inclusion and exclusion criteria, two reviewers screened controlled randomized trials which investigated glucocorticoid therapy in ARDS patients and independently extracted data. The quality of all of the included trials was evaluated based on blinding, randomization and other methods. A total of 14 studies with 1,441 patients met the inclusion criteria. The results of the meta-analysis demonstrated that glucocorticoid significantly reduced the overall mortality of patients with ARDS [relative ratio (RR), 0.68; 95% confidence interval (CI), 0.50–0.91; P<0.05], particularly with a low-dose of glucocorticoid (RR, 0.57; 95% CI, 0.39–0.84; P<0.05) at the early phase of ARDS (RR, 0.37; 95% CI, 0.16–0.86; P<0.05), and a longer duration of steroids (RR, 0.44; 95% CI, 0.30–0.64; P<0.05). Administration of steroids also significantly increased the number of days that patients remained alive and were off mechanical ventilation (RR, 3.08; 95% CI, 1.49–4.68; P<0.05) without significantly increasing the novel infection rate (RR, 1.00; 95% CI, 0.44–2.25; P<0.05). Due to inconsistencies and other limitations, the quality of the studies used for the meta-analysis of the effect of glucocorticoid on mortality was low. In conclusion, early use of low dose glucocorticoid may effectively reduce mortality in patients with ARDS. However, this conclusion may be affected by the limited quality of the studies included in the present meta-analysis.
format Online
Article
Text
id pubmed-5377286
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-53772862017-04-15 Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials Yang, Zhi-Gang Lei, Xiao-Li Li, Xiao-Liang Exp Ther Med Articles Previous clinical trials have investigated the effect of glucocorticoid therapy in acute respiratory distress syndrome (ARDS), with controversial results, particularly with regard to the early administration of low dose glucocorticoid. The present meta-analysis aimed to assess whether the application of glucocorticoid was able to reduce mortality in patients with ARDS. A literature search was performed using online databases, including MEDLINE, Embase, Cochrane and CNKI regardless of whether the studies were published in English or Chinese. Following assessment via inclusion and exclusion criteria, two reviewers screened controlled randomized trials which investigated glucocorticoid therapy in ARDS patients and independently extracted data. The quality of all of the included trials was evaluated based on blinding, randomization and other methods. A total of 14 studies with 1,441 patients met the inclusion criteria. The results of the meta-analysis demonstrated that glucocorticoid significantly reduced the overall mortality of patients with ARDS [relative ratio (RR), 0.68; 95% confidence interval (CI), 0.50–0.91; P<0.05], particularly with a low-dose of glucocorticoid (RR, 0.57; 95% CI, 0.39–0.84; P<0.05) at the early phase of ARDS (RR, 0.37; 95% CI, 0.16–0.86; P<0.05), and a longer duration of steroids (RR, 0.44; 95% CI, 0.30–0.64; P<0.05). Administration of steroids also significantly increased the number of days that patients remained alive and were off mechanical ventilation (RR, 3.08; 95% CI, 1.49–4.68; P<0.05) without significantly increasing the novel infection rate (RR, 1.00; 95% CI, 0.44–2.25; P<0.05). Due to inconsistencies and other limitations, the quality of the studies used for the meta-analysis of the effect of glucocorticoid on mortality was low. In conclusion, early use of low dose glucocorticoid may effectively reduce mortality in patients with ARDS. However, this conclusion may be affected by the limited quality of the studies included in the present meta-analysis. D.A. Spandidos 2017-04 2017-02-22 /pmc/articles/PMC5377286/ /pubmed/28413460 http://dx.doi.org/10.3892/etm.2017.4154 Text en Copyright: © Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Yang, Zhi-Gang
Lei, Xiao-Li
Li, Xiao-Liang
Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials
title Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials
title_full Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials
title_fullStr Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials
title_full_unstemmed Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials
title_short Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials
title_sort early application of low-dose glucocorticoid improves acute respiratory distress syndrome: a meta-analysis of randomized controlled trials
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377286/
https://www.ncbi.nlm.nih.gov/pubmed/28413460
http://dx.doi.org/10.3892/etm.2017.4154
work_keys_str_mv AT yangzhigang earlyapplicationoflowdoseglucocorticoidimprovesacuterespiratorydistresssyndromeametaanalysisofrandomizedcontrolledtrials
AT leixiaoli earlyapplicationoflowdoseglucocorticoidimprovesacuterespiratorydistresssyndromeametaanalysisofrandomizedcontrolledtrials
AT lixiaoliang earlyapplicationoflowdoseglucocorticoidimprovesacuterespiratorydistresssyndromeametaanalysisofrandomizedcontrolledtrials